PT2477603E - Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização - Google Patents
Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização Download PDFInfo
- Publication number
- PT2477603E PT2477603E PT107601403T PT10760140T PT2477603E PT 2477603 E PT2477603 E PT 2477603E PT 107601403 T PT107601403 T PT 107601403T PT 10760140 T PT10760140 T PT 10760140T PT 2477603 E PT2477603 E PT 2477603E
- Authority
- PT
- Portugal
- Prior art keywords
- vol
- formulation
- hyaluronidase
- immunoglobulin
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27704509P | 2009-09-17 | 2009-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2477603E true PT2477603E (pt) | 2016-06-16 |
Family
ID=43034406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107601403T PT2477603E (pt) | 2009-09-17 | 2010-09-16 | Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9084743B2 (2) |
| EP (1) | EP2477603B1 (2) |
| JP (1) | JP5734985B2 (2) |
| KR (1) | KR101441768B1 (2) |
| CN (1) | CN102655853B (2) |
| AU (1) | AU2010296017C1 (2) |
| BR (1) | BR112012005890B1 (2) |
| CA (1) | CA2774053C (2) |
| CO (1) | CO6460736A2 (2) |
| DK (1) | DK2477603T3 (2) |
| EA (1) | EA026112B1 (2) |
| ES (1) | ES2578478T3 (2) |
| HR (1) | HRP20160530T1 (2) |
| HU (1) | HUE028832T2 (2) |
| IN (1) | IN2012DN03219A (2) |
| MX (1) | MX2012003282A (2) |
| PL (1) | PL2477603T3 (2) |
| PT (1) | PT2477603E (2) |
| WO (1) | WO2011034604A2 (2) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| KR20140130512A (ko) | 2008-03-06 | 2014-11-10 | 할로자임, 아이엔씨 | 가용성 히알루로니다아제의 대규모 제조 |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| KR20100135291A (ko) | 2008-04-14 | 2010-12-24 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| CA2736141C (en) * | 2008-09-23 | 2018-03-20 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
| MX2012003282A (es) | 2009-09-17 | 2012-04-30 | Baxter Healthcare Sa | Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso. |
| DK2531218T3 (en) | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| US10420923B1 (en) | 2010-08-10 | 2019-09-24 | Amiram Katz | Method and device for intrathecal administering of immunoglobulin |
| EP2720712B1 (en) | 2011-06-17 | 2016-03-02 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| AU2012328880B2 (en) | 2011-10-24 | 2017-02-23 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| US11707409B2 (en) | 2011-10-25 | 2023-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| EP3130347B1 (en) | 2011-12-30 | 2019-09-18 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| IL300460A (en) * | 2012-07-24 | 2023-04-01 | Nissan Chemical Corp | A culture medium preparation, and a method for culturing cells or tissues by using the preparation |
| US9664671B2 (en) | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
| US10017805B2 (en) | 2012-08-23 | 2018-07-10 | Nissan Chemical Industries, Ltd. | Enhancing ingredients for protein production from various cells |
| PT2900247T (pt) * | 2012-09-26 | 2018-03-28 | Bone Therapeutics Sa | Composições contendo plasma tratado com dissolventes/detergentes e ácido hialurónico para serem utilizadas no tratamento de distúrbios músculo-esqueléticos |
| KR101454646B1 (ko) * | 2012-11-05 | 2014-10-27 | (주)한국비엠아이 | 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제 |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700486B2 (en) * | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| LT2994160T (lt) | 2013-05-06 | 2019-08-26 | Baxalta Incorporated | Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| WO2016029220A1 (en) * | 2014-08-22 | 2016-02-25 | Nectagen, Inc. | Affinity proteins and uses thereof |
| MX386886B (es) | 2014-09-09 | 2025-03-12 | Janssen Biotech Inc | Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias. |
| EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| ES2825704T3 (es) | 2014-12-03 | 2021-05-17 | Csl Behring Ag | Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| AU2016282674B2 (en) | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| DK3827845T3 (da) * | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| KR102624967B1 (ko) * | 2016-04-29 | 2024-01-16 | 이노비오 파마수티컬즈, 인크. | 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도 |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| EP3612221A1 (en) * | 2017-04-21 | 2020-02-26 | CSL Behring AG | Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| US12240875B2 (en) | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| CN111936513A (zh) * | 2018-01-31 | 2020-11-13 | 威斯塔解剖学和生物学研究所 | 用于抗呼吸道合胞病毒的核酸抗体构筑体 |
| CA3101462A1 (en) | 2018-06-08 | 2019-12-12 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| EP3636752A4 (en) | 2018-07-25 | 2021-04-28 | Alteogen, Inc. | NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN117100683A (zh) * | 2018-12-31 | 2023-11-24 | 拉尼医疗有限公司 | 使用可吞服药物递送装置递送到肠道内腔的治疗剂制剂 |
| MY204342A (en) | 2019-03-25 | 2024-08-24 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| CN110728044B (zh) * | 2019-09-30 | 2022-08-02 | 哈尔滨工程大学 | 一种针对于活塞环槽内气体压力状态的集成计算方法 |
| BR112022013554A2 (pt) | 2020-01-08 | 2022-09-06 | argenx BV | Métodos para tratar distúrbios do pênfigo |
| JP7622088B2 (ja) | 2020-08-07 | 2025-01-27 | アルテオジェン・インコーポレイテッド | 組換えヒアルロニダーゼの生産方法 |
| KR102265730B1 (ko) * | 2020-11-06 | 2021-06-17 | 주식회사 본에스티스 | 피부 주름 개선 및 미백용 화장료 조성물 |
| IL302860A (en) * | 2020-11-17 | 2023-07-01 | Janssen Sciences Ireland Unlimited Co | Treatment or prevention of a disease or disorder |
| WO2023012515A2 (en) * | 2021-08-02 | 2023-02-09 | argenx BV | Subcutaneous unit dosage forms |
| CA3232451A1 (en) * | 2021-09-14 | 2023-03-23 | Takeda Pharmaceutical Company Limited | Facilitated delivery of concentrated antibody formulations using hyaluronidase |
| EP4424301A4 (en) * | 2021-10-29 | 2025-11-19 | Alteogen Inc | Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product |
| CN119173446A (zh) | 2022-03-08 | 2024-12-20 | 赤盾医疗有限公司 | 机器人药物制备系统中的流体转移站 |
| CA3258000A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE |
| CN115957332B (zh) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用 |
| IL321611A (en) | 2022-12-22 | 2025-08-01 | Halozyme Inc | High-dose hyaluronidase enzyme formulations |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966906A (en) | 1961-10-11 | 1976-06-29 | Behringwerke Aktiengesellschaft | Disaggregated gamma globulin and process for preparing it |
| US3869436A (en) | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5420124B2 (2) | 1974-01-16 | 1979-07-20 | ||
| CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| JPS5731623B2 (2) | 1975-02-19 | 1982-07-06 | ||
| US4126605A (en) | 1975-12-29 | 1978-11-21 | Plasmesco Ag | Process of improving the compatibility of gamma globulins |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4165370A (en) | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
| US4124576A (en) | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
| JPS5420124A (en) | 1977-07-14 | 1979-02-15 | Green Cross Corp:The | Preparation of gamma-globulin intravenous injection |
| US4186192A (en) | 1978-12-18 | 1980-01-29 | Cutter Laboratories, Inc. | Stabilized immune serum globulin |
| US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
| US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| JPS5731623A (en) | 1980-07-30 | 1982-02-20 | Morishita Seiyaku Kk | Production of gamma-globulin for intravenous injection |
| JPS57128635A (en) | 1981-01-30 | 1982-08-10 | Morishita Seiyaku Kk | Pharmaceutical preparation of gamma-globulin for venoclysis |
| US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| US4396608A (en) | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| US4439421A (en) | 1982-08-30 | 1984-03-27 | Baxter Travenol Laboratories, Inc. | Stabilized gamma globulin concentrate |
| DK166763B1 (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| JPH0669961B2 (ja) | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| JPH0662436B2 (ja) | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
| JP2547556B2 (ja) | 1987-02-06 | 1996-10-23 | 株式会社 ミドリ十字 | ｒ−グロブリンの液状製剤 |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE3921528A1 (de) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | Messzelle fuer den elektrochemischen gasnachweis |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| AT402261B (de) | 1991-01-25 | 1997-03-25 | Immuno Ag | Komplex enthaltend den gerinnungsfaktor ix |
| JPH04346934A (ja) | 1991-05-24 | 1992-12-02 | Green Cross Corp:The | γ−グロブリンの液状製剤 |
| CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| CN1229385C (zh) | 1994-03-31 | 2005-11-30 | 安姆根有限公司 | 刺激巨核细胞生长和分化的组合物及方法 |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
| US5665069A (en) | 1996-07-19 | 1997-09-09 | Cumer; Patricia Lynn | Pressure-directed peribulbar anesthesia delivery device |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6123938A (en) | 1996-10-17 | 2000-09-26 | The Regents Of The University Of California | Human urinary hyaluronidase |
| US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
| US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| JP4270590B2 (ja) * | 1997-03-19 | 2009-06-03 | 田辺三菱製薬株式会社 | 免疫グロブリン製剤 |
| GB9705810D0 (en) * | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| AT405739B (de) | 1997-09-19 | 1999-11-25 | Immuno Ag | Verfahren zur reinigung von antithrombin iii |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
| WO2000002017A2 (en) | 1998-07-03 | 2000-01-13 | Neles Field Controls Oy | Method and arrangement for measuring fluid |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
| AU781839B2 (en) | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US20030212021A1 (en) | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
| WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| DE60144439D1 (de) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US6571605B2 (en) | 2001-01-19 | 2003-06-03 | Larry Keith Johnson | Constant-head soil permeameter for determining the hydraulic conductivity of earthen materials |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
| JP2005510229A (ja) | 2001-11-28 | 2005-04-21 | ネオーズ テクノロジーズ， インコーポレイテッド | アミダーゼを用いる糖タンパク質のリモデリング |
| US7192468B2 (en) | 2002-04-15 | 2007-03-20 | Fluor Technologies Corporation | Configurations and method for improved gas removal |
| JP2004147535A (ja) | 2002-10-29 | 2004-05-27 | Japan Science & Technology Agency | ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物 |
| KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
| CA2508948A1 (en) | 2002-12-16 | 2004-07-15 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| JP2004238392A (ja) * | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
| RU2358763C2 (ru) * | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| WO2004075923A2 (en) | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| JP4346934B2 (ja) | 2003-03-25 | 2009-10-21 | 日本碍子株式会社 | セラミックス構造体の製造方法 |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| TR201907313T4 (tr) | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | İki PEG zinciri içeren PEG türevleri. |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| US7572613B2 (en) | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
| CA2914170C (en) | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
| WO2009037566A2 (en) | 2007-06-19 | 2009-03-26 | Uvarkina Tamara P | Hyaluronidase and method of use thereof |
| KR20140130512A (ko) | 2008-03-06 | 2014-11-10 | 할로자임, 아이엔씨 | 가용성 히알루로니다아제의 대규모 제조 |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US20090311237A1 (en) | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| KR20100135291A (ko) | 2008-04-14 | 2010-12-24 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| CN103205407B (zh) | 2008-12-09 | 2016-03-16 | 哈洛齐梅公司 | 延长的可溶性ph20多肽及其用途 |
| MX2011012576A (es) | 2009-05-27 | 2012-05-08 | Baxter Int | Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo. |
| MX2012003282A (es) | 2009-09-17 | 2012-04-30 | Baxter Healthcare Sa | Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso. |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| MX348420B (es) | 2010-07-20 | 2017-06-12 | Halozyme Inc | Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios. |
| CA2810731A1 (en) | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph |
| EP2907504B1 (en) | 2011-02-08 | 2017-06-28 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| EP3130347B1 (en) | 2011-12-30 | 2019-09-18 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| HRP20181187T1 (hr) | 2012-04-04 | 2018-09-21 | Halozyme, Inc. | Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor |
-
2010
- 2010-09-16 MX MX2012003282A patent/MX2012003282A/es active IP Right Grant
- 2010-09-16 PT PT107601403T patent/PT2477603E/pt unknown
- 2010-09-16 CA CA2774053A patent/CA2774053C/en active Active
- 2010-09-16 EP EP10760140.3A patent/EP2477603B1/en active Active
- 2010-09-16 US US12/807,991 patent/US9084743B2/en active Active
- 2010-09-16 ES ES10760140.3T patent/ES2578478T3/es active Active
- 2010-09-16 DK DK10760140.3T patent/DK2477603T3/en active
- 2010-09-16 CN CN201080051813.3A patent/CN102655853B/zh active Active
- 2010-09-16 PL PL10760140.3T patent/PL2477603T3/pl unknown
- 2010-09-16 HU HUE10760140A patent/HUE028832T2/en unknown
- 2010-09-16 JP JP2012529751A patent/JP5734985B2/ja active Active
- 2010-09-16 BR BR112012005890-8A patent/BR112012005890B1/pt not_active IP Right Cessation
- 2010-09-16 IN IN3219DEN2012 patent/IN2012DN03219A/en unknown
- 2010-09-16 KR KR1020127009795A patent/KR101441768B1/ko active Active
- 2010-09-16 AU AU2010296017A patent/AU2010296017C1/en active Active
- 2010-09-16 EA EA201200490A patent/EA026112B1/ru unknown
- 2010-09-16 HR HRP20160530TT patent/HRP20160530T1/hr unknown
- 2010-09-16 WO PCT/US2010/002545 patent/WO2011034604A2/en not_active Ceased
-
2012
- 2012-04-12 CO CO12060153A patent/CO6460736A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012005890A2 (pt) | 2019-09-24 |
| WO2011034604A9 (en) | 2012-01-19 |
| CO6460736A2 (es) | 2012-06-15 |
| HK1173652A1 (zh) | 2013-05-24 |
| DK2477603T3 (en) | 2016-06-13 |
| EP2477603B1 (en) | 2016-03-30 |
| US20110066111A1 (en) | 2011-03-17 |
| JP5734985B2 (ja) | 2015-06-17 |
| EA026112B1 (ru) | 2017-03-31 |
| HUE028832T2 (en) | 2017-01-30 |
| BR112012005890B1 (pt) | 2023-01-17 |
| WO2011034604A3 (en) | 2011-12-01 |
| ES2578478T3 (es) | 2016-07-27 |
| KR20120105426A (ko) | 2012-09-25 |
| PL2477603T3 (pl) | 2016-10-31 |
| US9084743B2 (en) | 2015-07-21 |
| KR101441768B1 (ko) | 2014-09-17 |
| AU2010296017B2 (en) | 2013-06-06 |
| CA2774053A1 (en) | 2011-03-24 |
| AU2010296017A1 (en) | 2012-05-03 |
| CN102655853A (zh) | 2012-09-05 |
| CA2774053C (en) | 2015-04-28 |
| IN2012DN03219A (2) | 2015-10-23 |
| EP2477603A2 (en) | 2012-07-25 |
| HRP20160530T1 (hr) | 2016-07-29 |
| WO2011034604A2 (en) | 2011-03-24 |
| JP2013505237A (ja) | 2013-02-14 |
| EA201200490A1 (ru) | 2012-12-28 |
| AU2010296017C1 (en) | 2013-09-19 |
| CN102655853B (zh) | 2015-07-29 |
| MX2012003282A (es) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2477603E (pt) | Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização | |
| USRE49967E1 (en) | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase | |
| AU2017245352B2 (en) | Ph20 polypeptide variants, formulations and uses thereof | |
| HK1148699B (en) | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase | |
| HK1148699A (en) | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase | |
| HK1173652B (en) | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |